Compare FINV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | AGIO |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2017 | 2013 |
| Metric | FINV | AGIO |
|---|---|---|
| Price | $5.64 | $27.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.55 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 1.1M | 664.7K |
| Earning Date | 03-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $6.02 | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.70 | $22.24 |
| 52 Week High | $10.90 | $46.00 |
| Indicator | FINV | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 46.39 |
| Support Level | $5.44 | $26.48 |
| Resistance Level | $5.96 | $29.49 |
| Average True Range (ATR) | 0.25 | 1.06 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 34.96 | 29.67 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.